Swiss drug company Novartis has hinted that it could charge as much as $4 to $5 million for a new gene therapy, according to Reuters.
Rare disease: The gene replacement treatment, not yet approved, is for type 1 spinal muscular atrophy, a fatal inherited disease that strikes 1 in 20,000 toddlers. A single dose of the therapy appears to prevent the disease if given shortly after birth. In other words, it looks like a true cure.
Strike it rich: The gene therapy technology was spun out by Nationwide Children’s Hospital into a startup, AveXis, which tested it in a dozen or so children. Earlier this year, Novartis acquired AveXis for almost $9 billion. The deal made a few people very wealthy. It also pretty much guaranteed an eye-watering price tag.
Pay up: Novartis hasn’t announced a final price, but according to Reuters, Dave Lennon, president of AveXis, said during a conference call that “four million dollars is a significant amount of money, but we believe this is a cost-effective point.” The previous record price for a drug was about $1 million for Glybera, also a gene therapy.
Why so much? Rare diseases are, well, really rare. And drug companies think in terms of blockbusters. The only way to turn a rare-disease treatment that’s given just once into a profit-maker is to charge ultra-high prices.
Life or death: Expect Novartis to face tough questions going forward. One critic on Twitter noted that ransoms paid to criminal gangs to release hostages are often only about $2 million.
How scientists want to make you young again
Research labs are pursuing technology to “reprogram” aging bodies back to youth.
Human brain cells transplanted into baby rats’ brains grow and form connections
When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.
Inside the billion-dollar meeting for the mega-rich who want to live forever
Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.
The debate over whether aging is a disease rages on
In its latest catalogue of health conditions, the World Health Organization almost equated old age with disease. Then it backed off.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.